Triple-negative breast cancer (sometimes abbreviated TNBC) refers to any breast cancer that does not express the genes for estrogen receptor (ER), progesterone receptor (PR) and Her2/neu. This makes it more difficult to treat since most hormone therapies target one of the three receptors, so triple-negative cancers often require combination therapies.
The symposium will focus on drug discovery, biomarkers and treatment aspects of TNBC. Participants will gain a broad exposure to the fundamental mechanisms driving TNBC through presentations from three speakers discussing the recent advances in this cancer subtype. The Networking session at the end of the symposium will focus on Horizon 2020 funding opportunities for both academia and industry in the field of cancer and personalised medicine.
This event is FREE to attend and you can send your registration by filling the form at the end of this page.
The meeting is supported and arranged in co-operation with:
please contact either
|09:00–09:15||Registration and Light Refreshments|
|09:15–09:30||Welcome and Introduction|
|09:30–10:10||Development of Small Molecule Anti-Metastatic Agents for Potential Treatment of Triple Negative Breast Cancer
Prof. Andrew Westwell, Cardiff University, United Kingdom
|10:10–10:50||New Prognostic Biomarkers for Triple Negative Breast Cancer
Prof. Emiel Janssen, Stavanger University Hospital, Norway
|10:50–11:30||Glyco-TROLL – Innovative treatment for (highly) glycolytic cancers
Dr. Claudia Bøen, Arctic Pharma AS, Norway
|11:30–12:30||Networking Session: Horizon 2020 – Cancer and Personalised Medicine
Dr. Gupta Udatha, Oslo Cancer Cluster